Publications by authors named "Samar Alanazi"

Claim this Profile
E
Early visual and clinical outcomes of transepithelial photorefractive keratectomy versus transepithelial keratectomy with smart pulse technology for myopia.
Turad Alkadi, Samar Alanazi, Abdulrahman Algwaiz, Salman Alyahya, Faris Binyousef

Oman J Ophthalmol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cultural adaptations of third-wave psychotherapies in Gulf Cooperation Council countries: A systematic review.
Duaa H Alrashdi, Aisha H Alyafei, Samar A Alanazi, Carly Meyer, Rebecca L Gould

Transcult Psychiatry· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.
Samar M Alanazi, Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Hima Patel

PLoS One· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER3 Alterations in Cancer and Potential Clinical Implications.
Mary Kate Kilroy, SoYoung Park, Wasim Feroz, Hima Patel, Rosalin Mishra, Samar Alanazi

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practice of ear candling during lockdown due to COVID-19 in the Kingdom of Saudi Arabia.
Samar M Alanazi, Norah A Albdaya, Lama S Alhosaini, Fahad Z Alotaibi, Alhanouf A AlQabbani

J Family Med Prim Care· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma.
Hima Patel, Rosalin Mishra, Nour Yacoub, Samar Alanazi, Mary Kate Kilroy

Cancers (Basel)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.
Rosalin Mishra, Hima Patel, Samar Alanazi, Mary Kate Kilroy, Joan T Garrett

Int J Mol Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth.
Rosalin Mishra, Long Yuan, Hima Patel, Aniruddha S Karve, Haizhou Zhu, Samar Alanazi

Int J Mol Sci· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels.
Long Yuan, Rosalin Mishra, Hima Patel, Samar Alanazi, Xin Wei

Cancers (Basel)· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Advances in the Treatment of BRAF-Mutant Melanoma.
Hima Patel, Nour Yacoub, Rosalin Mishra, Aaron White, Yuan Long, Samar Alanazi

Cancers (Basel)· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating HER3 mutations in breast cancer.
Rosalin Mishra, Samar Alanazi, Long Yuan, Thomas Solomon, Tarjani M Thaker

Oncotarget· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER3 signaling and targeted therapy in cancer.
Rosalin Mishra, Hima Patel, Samar Alanazi, Long Yuan, Joan T Garrett

Oncol Rev· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis